Pipeline Review on Secondary Hyperparathyroidism - H1 2020 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Secondary Hyperparathyroidism - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

The latest Pharmaceutical and Healthcare disease pipeline guide Secondary Hyperparathyroidism - Pipeline Review, H1 2020, provides an overview of the Secondary Hyperparathyroidism (Hormonal Disorders) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Secondary Hyperparathyroidism (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Companies Mentioned

• Amgen Inc
• Cinkate Corp
• EA Pharma Co Ltd
• Lupin Ltd
• Mitsubishi Tanabe Pharma Corp
• Novadiol Inc
• OPKO Health Inc
• TaiRx Inc
• Vidasym Inc
  

The report reviews of key players involved in therapeutic development for Secondary Hyperparathyroidism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 1, 3 and 2 respectively.

The guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Secondary Hyperparathyroidism (Hormonal Disorders).
• The pipeline guide reviews pipeline therapeutics for Secondary Hyperparathyroidism (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Secondary Hyperparathyroidism (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Secondary Hyperparathyroidism (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Secondary Hyperparathyroidism (Hormonal Disorders)

Reasons to buy

1. Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
2. Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
3. Find and recognize significant and varied types of therapeutics under development for Secondary Hyperparathyroidism (Hormonal Disorders).
4. Classify potential new clients or partners in the target demographic.
5. Develop tactical initiatives by understanding the focus areas of leading companies.
6. Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
7. Formulate corrective measures for pipeline projects by understanding Secondary Hyperparathyroidism (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
8. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
9. Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
   

Key Topics Covered:

• Introduction
• Report Coverage
• Secondary Hyperparathyroidism - Overview
• Secondary Hyperparathyroidism - Therapeutics Development
• Pipeline Overview
• Pipeline by Companies
• Products under Development by Companies
• Secondary Hyperparathyroidism - Therapeutics Assessment
• Assessment by Target
• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type
• Secondary Hyperparathyroidism - Companies Involved in Therapeutics Development
• Secondary Hyperparathyroidism - Drug Profiles
• AJT-240 - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• calcifediol ER - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• Secondary Hyperparathyroidism - Dormant Projects
• Secondary Hyperparathyroidism - Discontinued Products
• Secondary Hyperparathyroidism - Product Development Milestones
• Featured News & Press Releases
• Appendix
• Methodology
• Coverage
• Secondary Research
• Primary Research
• Expert Panel Validation
• Contact Us
• Disclaimer

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/9xwzpo